logo-loader
viewANGLE PLC

ANGLE technology used in cutting-edge research featured in science journal Nature

Parstortix was central to the analysis carried out by a team at the University of Basel, in Switzerland

cancer cells
Scientists have come closer to understanding why cancer spreads in the way it does

ANGLE PLC (LON:AGL), the med-tech firm at the forefront of cancer research, said its liquid biopsy system has been used in research featured in the prestigious science journal Nature.

Parstortix was central to the analysis carried out by a team at the University of Basel, in Switzerland, which highlighted the role of immune cells assigned to protect the body from the disease in actually promoting the spread of cancer - a process called metastasis.

READ: ANGLE on track to complete key Parsortix study in current quarter

The research published in Nature identified a subset of circulating tumour cell clusters using ANGLE's technology that was demonstrated to be associated with greatly increased metastatic ability.

Understanding the role of the patient’s own immune system in aiding cancer spread opens the potential for the development of new therapies that impede the process.

"Research into CTC clusters using the Parsortix system has the potential to change the way that cancer is treated,” said ANGLE founder and chief executive Andrew Newland.

“The publication of the University of Basel's research in Nature on CTC-neutrophil clusters, following the previous publication in Cell, is a tremendous achievement for Basel, one of ANGLE's leading customers.

“We are delighted that the harvesting of CTC clusters, using the Parsortix system, is a key element in the drive to block the process of cancer metastasis that is responsible for over 90% of deaths from cancer."

Quick facts: ANGLE PLC

Price: 65.5 GBX

AIM:AGL
Market: AIM
Market Cap: £113.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ANGLE PLC submits its flagship Parsortix liquid biopsy diagnostic to the FDA

ANGLE PLC (LON:AGL) (OTCQX:ANPCY) CEO Andrew Newland tells Proactive the company has submitted its patent-protected, flagship Parsortix liquid biopsy diagnostic for clearance to the FDA.  Newland says this is a tremendous opportunity for ANGLE, as he says ANGLE is the first company to...

3 weeks ago

2 min read